Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Liver Diseases

Free Subscription 22.04.2024 1 Am J Gastroenterol 1 Ann Intern Med 1 Biochem Biophys Res Commun 6 BMC Cancer 1 BMC Gastroenterol 2 Br J Surg 1 Cancer 1 Cancer Res 6 Dig Dis Sci 1 Gastrointest Endosc 2 Gut 25 Hepatology 1 Indian J Gastroenterol 1 J Gastroenterol Hepatol 1 PLoS Genet 6 PLoS One 1 Proc Natl Acad Sci U S A 1 Radiology 7 Semin Liver Dis

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Gastroenterol

1. HUME SJ, Holmes JA, Thompson AJ
   Individualizing the Approach to Stopping Nucleos(t)ide Analogs: Can We Use a Low HBsAg Threshold to Predict a High Chance of Functional Cure and Minimal Risk of Hepatic Decompensation?
   Am J Gastroenterol. 2024 Apr 15. doi: 10.14309/ajg.0000000000002766.
   PubMed        
   
   

   
   Ann Intern Med

2. ANVARI S, Dadgar K, Galts C, Bretthauer M, et al
   Gastroenterology/Hepatology: What You May Have Missed in 2023.
   Ann Intern Med. 2024 Apr 16. doi: 10.7326/M24-0505.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

3. CAO Y, Wang S, Zhang M, Lai B, et al
   PFKFB3-mediated glycolysis in hepatic stellate cells promotes liver regeneration.
   Biochem Biophys Res Commun. 2024;712-713:149958.
   PubMed         Abstract available
   
   

   
   BMC Cancer

4. HAO X, Xu L, Lan X, Li B, et al
   Impact of hepatic inflammation and fibrosis on the recurrence and long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after hepatectomy.
   BMC Cancer. 2024;24:475.
   PubMed         Abstract available
   
   
5. ZONG K, Lin C, Luo K, Deng Y, et al
   Ferroptosis-related lncRNA NRAV affects the prognosis of hepatocellular carcinoma via the miR-375-3P/SLC7A11 axis.
   BMC Cancer. 2024;24:496.
   PubMed         Abstract available
   
   
6. HUANG Y, Chen D, Bai Y, Zhang Y, et al
   ESCO2's oncogenic role in human tumors: a pan-cancer analysis and experimental validation.
   BMC Cancer. 2024;24:452.
   PubMed         Abstract available
   
   
7. YOU X, Qiu J, Li Q, Zhang Q, et al
   Astragaloside IV-PESV inhibits prostate cancer tumor growth by restoring gut microbiota and microbial metabolic homeostasis via the AGE-RAGE pathway.
   BMC Cancer. 2024;24:472.
   PubMed         Abstract available
   
   
8. CHANG X, Li X, Sun P, Li Z, et al
   HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study.
   BMC Cancer. 2024;24:480.
   PubMed         Abstract available
   
   
9. LI Y, Chen Z, Tian S, Han X, et al
   Stereotactic ablative brachytherapy versus percutaneous microwave ablation as salvage treatments for lung oligometastasis from colorectal cancer.
   BMC Cancer. 2024;24:481.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

10. XIE H, Hong T, Liu W, Jia X, et al
    Interpretable machine learning-based clinical prediction model for predicting lymph node metastasis in patients with intrahepatic cholangiocarcinoma.
    BMC Gastroenterol. 2024;24:137.
    PubMed         Abstract available
    
    

    
    Br J Surg

11. AKABANE M, Bekki Y, Imaoka Y, Inaba Y, et al
    Impact of donor characteristics on hepatocellular carcinoma recurrence after liver transplantation.
    Br J Surg. 2024;111:znae080.
    PubMed        
    
    
12. JOLIAT GR, de Man R, Rijckborst V, Cimino M, et al
    Long-term outcomes of ruptured hepatocellular carcinoma: international multicentre study.
    Br J Surg. 2024;111:znae093.
    PubMed        
    
    

    
    Cancer

13. NIERENGARTEN MB
    Global phase 3 results show that bevacizumab with immunotherapy has activity in liver cancer.
    Cancer. 2024;130:1547-1548.
    PubMed        
    
    

    
    Cancer Res

14. LIU X, Wang X, Yang Q, Luo L, et al
    Th17 cells secrete TWEAK to trigger epithelial-mesenchymal transition and promote colorectal cancer liver metastasis.
    Cancer Res. 2024 Feb 9. doi: 10.1158/0008-5472.CAN-23-2123.
    PubMed         Abstract available
    
    

    
    Dig Dis Sci

15. MCCURDY H, Nobbe A, Scott D, Patton H, et al
    Organizational and Implementation Factors Associated with Cirrhosis Care in the Veterans Health Administration.
    Dig Dis Sci. 2024 Apr 14. doi: 10.1007/s10620-024-08409.
    PubMed         Abstract available
    
    
16. BEHARI J
    Spleen Stiffness Measurement in Metabolic Dysfunction-Associated Steatotic Liver Disease-Value Added or Work in Progress?
    Dig Dis Sci. 2024;69:1093-1095.
    PubMed        
    
    
17. WILLIAMS EE, Mladenovic A, Ranginani D, Weber R, et al
    Role of Spleen Stiffness Measurement in the Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Dig Dis Sci. 2024;69:1444-1453.
    PubMed         Abstract available
    
    
18. GU Y, Chen G, Ning X
    Homeobox Protein BarH-like 1 Promotes Gastric Cancer Progression by Activating Coiled-Coil Domain-Containing Protein 178.
    Dig Dis Sci. 2024 Feb 15. doi: 10.1007/s10620-024-08312.
    PubMed         Abstract available
    
    
19. POP A, Halegoua-DeMarzio D, Barnhart H, Kleiner D, et al
    Amiodarone and Dronedarone Causes Liver Injury with Distinctly Different Clinical Presentations.
    Dig Dis Sci. 2024;69:1479-1487.
    PubMed         Abstract available
    
    
20. KHAMSEH ME, Malek M, Jahangiri S, Nobarani S, et al
    Insulin Resistance/Sensitivity Measures as Screening Indicators of Metabolic-Associated Fatty Liver Disease and Liver Fibrosis.
    Dig Dis Sci. 2024;69:1430-1443.
    PubMed         Abstract available
    
    

    
    Gastrointest Endosc

21. MATSUMOTO K, Kato H, Matsumi A, Miyamoto K, et al
    Detection of residual stones by peroral direct cholangioscopy in patients with intrahepatic stones after hepaticojejunostomy: A prospective study (with video).
    Gastrointest Endosc. 2024 Apr 15:S0016-5107(24)00234.
    PubMed         Abstract available
    
    

    
    Gut

22. SUDDLE A, Reeves H, Hubner R, Marshall A, et al
    British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults.
    Gut. 2024 Apr 16:gutjnl-2023-331695. doi: 10.1136/gutjnl-2023-331695.
    PubMed         Abstract available
    
    
23. LIU J, MacNaughtan J, Kerbert AJC, Portlock T, et al
    Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbab le, gut-restricted adsorbent in models and patients with cirrhosis.
    Gut. 2024 Apr 15:gutjnl-2023-330699. doi: 10.1136/gutjnl-2023-330699.
    PubMed         Abstract available
    
    

    
    Hepatology

24. LENZ D, Schlieben LD, Shimura M, Bianzano A, et al
    Genetic landscape of pediatric acute liver failure of indeterminate origin.
    Hepatology. 2024;79:1075-1087.
    PubMed         Abstract available
    
    
25. GISH RG, Wong RJ, Di Tanna GL, Kaushik A, et al
    Association between hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000642.
    PubMed         Abstract available
    
    
26. AJMERA V, Tesfai K, Sandoval E, Lopez S, et al
    Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes.
    Hepatology. 2024;79:1098-1106.
    PubMed         Abstract available
    
    
27. TONIUTTO P, Shalaby S, Mameli L, Morisco F, et al
    Role of sex in liver tumor occurrence and clinical outcomes: A comprehensive review.
    Hepatology. 2024;79:1141-1157.
    PubMed         Abstract available
    
    
28. SANTOS AA, Delgado TC, Marques V, Ramirez-Moncayo C, et al
    Spatial metabolomics and its application in the liver.
    Hepatology. 2024;79:1158-1179.
    PubMed         Abstract available
    
    
29. LEE YT, Tseng HR, Yang JD
    Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block.
    Hepatology. 2024 Apr 19. doi: 10.1097/HEP.0000000000000898.
    PubMed        
    
    
30. GUO C, Liu Z, Fan H, Wang H, et al
    Machine learning-based plasma metabolomic profiles for predicting long-term complications of cirrhosis.
    Hepatology. 2024 Apr 17. doi: 10.1097/HEP.0000000000000879.
    PubMed         Abstract available
    
    
31. 
    Erratum: Overexpressed-eIF3I interacted and activated oncogenic Akt1 is a theranostic target in human hepatocellular carcinoma.
    Hepatology. 2024;79:E150-E151.
    PubMed        
    
    
32. HAZARI Y, Chevet E, Bailly-Maitre B, Hetz C, et al
    ER stress signaling at the interphase between MASH and hepatocellular carcinoma.
    Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000893.
    PubMed         Abstract available
    
    
33. PRZYBYSZEWSKI EM, Bhan I, Yarze JC
    Letter to the Editor: On the use of non-selective beta blockers in cirrhosis.
    Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000888.
    PubMed        
    
    
34. GARCIA-TSAO G, Kaplan DE
    Reply: On the use of non-selective beta blockers in cirrhosis.
    Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000889.
    PubMed        
    
    
35. VOLK ML
    Innovations in Healthcare Delivery for Patients with Cirrhosis.
    Hepatology. 2024 Apr 16. doi: 10.1097/HEP.0000000000000892.
    PubMed        
    
    
36. KANWAL F, Neuschwander-Tetri BA, Loomba R, Rinella ME, et al
    Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.
    Hepatology. 2024;79:1212-1219.
    PubMed         Abstract available
    
    
37. NABI O, Lapidus N, Boursier J, de Ledinghen V, et al
    Reply: Concerns regarding the use of Fatty Liver Index in studies of lean NAFLD.
    Hepatology. 2024;79:E130-E131.
    PubMed        
    
    
38. ZAHRAWI FM, Mehal WZ
    Letter to the Editor: Concerns regarding the use of fatty liver index in studies of lean NAFLD.
    Hepatology. 2024;79:E129.
    PubMed        
    
    
39. STOCKDALE AJ, Degasperi E
    HDV RNA and liver disease progression: What do we know?
    Hepatology. 2024;79:983-985.
    PubMed        
    
    
40. CORPECHOT C, Lemoinne S, Soret PA, Chazouilleres O, et al
    Reply: Improving access to transient elastography data for Real-World Prognostic Applications in primary biliary cholangitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000746.
    PubMed        
    
    
41. WIEGAND J, Franke A, Stein K, Trautwein C, et al
    Letter to the Editor: Improving access to transient elastography data for real-world prognostic applications in primary biliary cholangitis.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000744.
    PubMed        
    
    
42. DESERT R, Foucher F, Guillout M, Nieto N, et al
    Reply: Intratumor fibrotic HCC, a subtype matching the Hoshida S1 subclass?
    Hepatology. 2024;79:E141-E143.
    PubMed        
    
    
43. WANG TC, Xiao YD, Zhou P
    Letter to the Editor: Intratumor fibrotic HCC, a subtype matching the Hoshida S1 subclass?
    Hepatology. 2024;79:E140.
    PubMed        
    
    
44. LIU H, Li H, Wang DX, Li T, et al
    Letter to the Editor: Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
    Hepatology. 2024;79:E144-E145.
    PubMed        
    
    
45. DALBENI A, Mantovani A, Lombardi R, Ravaioli F, et al
    Reply: Diagnostic accuracy of AGILE3+ score for advanced fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Hepatology. 2024;79:E146-E147.
    PubMed        
    
    
46. KIRK FT, Munk DE, Swenson ES, Quicquaro AM, et al
    Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64 Cu PET/CT study in healthy humans.
    Hepatology. 2024;79:1065-1074.
    PubMed         Abstract available
    
    
47. SQUIRES JE, Horslen SP
    Incorporation of genetic testing into the diagnostic algorithms of PALF: The time is now.
    Hepatology. 2024;79:970-972.
    PubMed        
    
    
48. DALBENI A, Lombardi R, Henrique M, Zoncape M, et al
    Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis.
    Hepatology. 2024;79:1107-1116.
    PubMed         Abstract available
    
    

    
    Indian J Gastroenterol

49. AGARWAL S, Sharma S, Grover I, Singh N, et al
    Longitudinal changes in bone mineral density may be associated with long-term survival in patients with cirrhosis: A proof of concept of study.
    Indian J Gastroenterol. 2024 Apr 15. doi: 10.1007/s12664-023-01504.
    PubMed         Abstract available
    
    

    
    J Gastroenterol Hepatol

50. LOON E, Narvaez-Barbecho C, Ortiz JP, Balderramo D, et al
    Impact of self-reported ancestry on the epidemiology of hepatocellular carcinoma.
    J Gastroenterol Hepatol. 2024 Apr 13. doi: 10.1111/jgh.16578.
    PubMed        
    
    

    
    PLoS Genet

51. MA RK, Tsai PY, Farghli AR, Shumway A, et al
    DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma.
    PLoS Genet. 2024;20:e1011216.
    PubMed         Abstract available
    
    

    
    PLoS One

52. PASTROVIC F, Novak R, Grgurevic I, Hrkac S, et al
    Serum proteomic profiling of patients with compensated advanced chronic liver disease with and without clinically significant portal hypertension.
    PLoS One. 2024;19:e0301416.
    PubMed         Abstract available
    
    
53. BAEK M, Kim M, Choi HI, Binas B, et al
    Identification of differentially expressed mRNA/lncRNA modules in acutely regorafenib-treated sorafenib-resistant Huh7 hepatocellular carcinoma cells.
    PLoS One. 2024;19:e0301663.
    PubMed         Abstract available
    
    
54. GURUN M, Brennan P, Handjiev S, Khatib A, et al
    Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis.
    PLoS One. 2024;19:e0299507.
    PubMed         Abstract available
    
    
55. CHAVEZ-TAPIA NC, Sanchez-Jimenez BA, Vidana-Perez D, Corrales-Rosas B, et al
    Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study.
    PLoS One. 2024;19:e0290632.
    PubMed         Abstract available
    
    
56. WU T, Yang H, Li J, Fang H, et al
    Jolkinolide B inhibits the progression of hepatocellular carcinoma by regulating Musashi-2 protein.
    PLoS One. 2024;19:e0299920.
    PubMed         Abstract available
    
    
57. GABUZA K, Mabuda TI, Patel O, Khuboni N, et al
    Afriplex GRTTM extract attenuates hepatic steatosis in an in vitro model of NAFLD.
    PLoS One. 2024;19:e0297572.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

58. GU L, Du Y, Chen J, Hasan MN, et al
    Cullin 3 RING E3 ligase inactivation causes NRF2-dependent NADH reductive stress, hepatic lipodystrophy, and systemic insulin resistance.
    Proc Natl Acad Sci U S A. 2024;121:e2320934121.
    PubMed         Abstract available
    
    

    
    Radiology

59. LYU L, Xu P
    Hepatic CT Perfusion in Budd-Chiari Syndrome before and after Intervention.
    Radiology. 2024;311:e232426.
    PubMed        
    
    

    
    Semin Liver Dis

60. BECH KT, Lindvig KP, Thiele M, Castera L, et al
    Algorithms for Early Detection of Silent Liver Fibrosis in the Primary Care Setting.
    Semin Liver Dis. 2024;44:23-34.
    PubMed         Abstract available
    
    
61. EL-KASSAS M, Awad A, Elbadry M, Arab JP, et al
    Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Semin Liver Dis. 2024;44:54-68.
    PubMed         Abstract available
    
    
62. BESSONE F, Hillotte GL, Ahumada N, Jaureguizahar F, et al
    UDCA for Drug-Induced Liver Disease: Clinical and Pathophysiological Basis.
    Semin Liver Dis. 2024;44:1-22.
    PubMed         Abstract available
    
    
63. TUTUSAUS A, Morales A, Garcia de Frutos P, Mari M, et al
    GAS6/TAM Axis as Therapeutic Target in Liver Diseases.
    Semin Liver Dis. 2024;44:99-114.
    PubMed         Abstract available
    
    
64. MOUZAKI M, Woo JG, Divanovic S
    Gestational and Developmental Contributors of Pediatric MASLD.
    Semin Liver Dis. 2024;44:43-53.
    PubMed         Abstract available
    
    
65. CANIVET CM, Boursier J, Loomba R
    New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice.
    Semin Liver Dis. 2024;44:35-42.
    PubMed         Abstract available
    
    
66. ROMERO-GOMEZ M, Arab JP, Oliveira CP, Hernandez M, et al
    Is There a Safe Alcohol Consumption Limit for the General Population and in Patients with Liver Disease?
    Semin Liver Dis. 2024;44:69-78.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.